Trial Outcomes & Findings for Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer (NCT NCT02953782)

NCT ID: NCT02953782

Last Updated: 2021-03-01

Results Overview

DLT was defined as any Grade (GR) 3 or greater adverse event (AE) that was assessed as related to study treatment with the exceptions of: GR 3: anemia (hemolytic anemia that is medically significant tis considered a DLT), indirect/unconjugated hyperbilirubinemia, electrolyte abnormalities, elevation in alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase that resolved to ≤ Grade 2 with supportive care within 1 week and is not associated with other clinically significant consequences; nausea, vomiting, or diarrhea that resolved to ≤ Grade 2 with supportive care within 72 hours; fatigue that resolved to ≤ Grade 2 within 2 weeks on study; drug-related infusion reactions in the absence of an optimal pretreatment regimen; tumor lysis syndrome or electrolyte disturbances, hypomagnesemia, that resolved to ≤ Grade 2 or baseline within 1 week; GR 3 or 4: lymphopenia or leukopenia.

• Recruitment status: COMPLETED
• Study phase: PHASE1/PHASE2
• Target enrollment: 78 participants
• Primary outcome timeframe: From first dose up to Day 28
• Results posted on: 2021-03-01

Participant Flow

Participants were enrolled at study sites in United States. The first participant was screened on 02 November 2016. The last study visit occurred on 10 February 2020.

105 participants were screened.

Participant milestones

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced colorectal cancer (CRC) who were KRAS wild type (KRASwt) and were refractory to anti-EGFRmAb therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRAS mutation (KRASm) who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
Phase 1b (Maximum Duration: 14.3 Months) STARTED	6	3	9	8	6	0	0	0
Phase 1b (Maximum Duration: 14.3 Months) COMPLETED	0	0	0	0	0	0	0	0
Phase 1b (Maximum Duration: 14.3 Months) NOT COMPLETED	6	3	9	8	6	0	0	0
Phase 2 (Maximum Duration: 11.1 Months) STARTED	0	0	0	0	0	16	15	15
Phase 2 (Maximum Duration: 11.1 Months) COMPLETED	0	0	0	0	0	0	0	0
Phase 2 (Maximum Duration: 11.1 Months) NOT COMPLETED	0	0	0	0	0	16	15	15

Reasons for withdrawal

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced colorectal cancer (CRC) who were KRAS wild type (KRASwt) and were refractory to anti-EGFRmAb therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRAS mutation (KRASm) who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
Phase 1b (Maximum Duration: 14.3 Months) Death	5	2	6	6	4	0	0	0
Phase 1b (Maximum Duration: 14.3 Months) Withdrawal by Subject	1	0	2	0	1	0	0	0
Phase 1b (Maximum Duration: 14.3 Months) Discontinued by Sponsor	0	1	0	1	1	0	0	0
Phase 1b (Maximum Duration: 14.3 Months) Participant placed in hospice care	0	0	1	1	0	0	0	0
Phase 2 (Maximum Duration: 11.1 Months) Death	0	0	0	0	0	14	11	8
Phase 2 (Maximum Duration: 11.1 Months) Withdrawal by Subject	0	0	0	0	0	1	2	3
Phase 2 (Maximum Duration: 11.1 Months) Discontinued by Sponsor	0	0	0	0	0	1	1	4
Phase 2 (Maximum Duration: 11.1 Months) Lost to Follow-up	0	0	0	0	0	0	1	0

Baseline Characteristics

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Baseline characteristics by cohort

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=9 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=8 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=16 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=15 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=15 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Total n=78 Participants Total of all reporting groups
Age, Continuous	62.6 years STANDARD_DEVIATION 6.72 • n=5 Participants	68.6 years STANDARD_DEVIATION 11.39 • n=7 Participants	57.3 years STANDARD_DEVIATION 7.05 • n=5 Participants	52.4 years STANDARD_DEVIATION 10.97 • n=4 Participants	63.6 years STANDARD_DEVIATION 9.50 • n=21 Participants	59.7 years STANDARD_DEVIATION 14.38 • n=10 Participants	58.9 years STANDARD_DEVIATION 14.41 • n=115 Participants	57.4 years STANDARD_DEVIATION 5.80 • n=6 Participants	58.9 years STANDARD_DEVIATION 11.13 • n=6 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	6 Participants n=10 Participants	8 Participants n=115 Participants	5 Participants n=6 Participants	27 Participants n=6 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	3 Participants n=7 Participants	7 Participants n=5 Participants	6 Participants n=4 Participants	4 Participants n=21 Participants	10 Participants n=10 Participants	7 Participants n=115 Participants	10 Participants n=6 Participants	51 Participants n=6 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	4 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=6 Participants	8 Participants n=6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	5 Participants n=5 Participants	3 Participants n=7 Participants	8 Participants n=5 Participants	8 Participants n=4 Participants	5 Participants n=21 Participants	12 Participants n=10 Participants	13 Participants n=115 Participants	11 Participants n=6 Participants	65 Participants n=6 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants	4 Participants n=6 Participants	5 Participants n=6 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	1 Participants n=6 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	3 Participants n=6 Participants	5 Participants n=6 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=6 Participants	5 Participants n=6 Participants
Race (NIH/OMB) White	5 Participants n=5 Participants	3 Participants n=7 Participants	7 Participants n=5 Participants	8 Participants n=4 Participants	6 Participants n=21 Participants	8 Participants n=10 Participants	10 Participants n=115 Participants	8 Participants n=6 Participants	55 Participants n=6 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	4 Participants n=10 Participants	3 Participants n=115 Participants	4 Participants n=6 Participants	12 Participants n=6 Participants

PRIMARY outcome

Timeframe: From first dose up to Day 28

Population: DLT Evaluable Analysis Set included participants who received at least 1 dose of any study drugs during Phase 1b if the participant either experienced a DLT any time during the DLT assessment period (the first 4 weeks of treatment) or completed at least 4 infusions of magrolimab and 2 infusions of cetuximab.

DLT was defined as any Grade (GR) 3 or greater adverse event (AE) that was assessed as related to study treatment with the exceptions of:

GR 3: anemia (hemolytic anemia that is medically significant tis considered a DLT), indirect/unconjugated hyperbilirubinemia, electrolyte abnormalities, elevation in alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase that resolved to ≤ Grade 2 with supportive care within 1 week and is not associated with other clinically significant consequences; nausea, vomiting, or diarrhea that resolved to ≤ Grade 2 with supportive care within 72 hours; fatigue that resolved to ≤ Grade 2 within 2 weeks on study; drug-related infusion reactions in the absence of an optimal pretreatment regimen; tumor lysis syndrome or electrolyte disturbances, hypomagnesemia, that resolved to ≤ Grade 2 or baseline within 1 week;

GR 3 or 4: lymphopenia or leukopenia.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=9 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=7 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=9 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Percentage of Participants With Dose Limiting Toxicities (DLT)	16.7 percentage of participants	0.0 percentage of participants	0.0 percentage of participants	14.3 percentage of participants	0.0 percentage of participants	0.0 percentage of participants	—	—	—

PRIMARY outcome

Timeframe: From first dose date up to last dose date plus 30 days (maximum: 15.3 months)

Population: All Treated included all participants who received at least 1 dose of any study drugs.

An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as AEs worsening or occurring during or after a participant's first exposure to study drug and within 30 days after the last administration of study drug or initiation of new anticancer therapy, whichever occurred first.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=10 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=7 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=14 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=15 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=14 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only n=3 Participants Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants

PRIMARY outcome

Timeframe: From Screening until 38.89 months (assessed on Day 1 of Cycle 3 then every 8 weeks [Q8W] from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

Population: Participants in All Treated with available data were analyzed. Efficacy results were planned to be reported separately for all CRC participants with KRASwt and KRASm tumors.

Objective response rate was defined as the percentage of participants with objective response which consisted of complete response (CR)+ partial response (PR) determined by RECIST v 1.1. CR: Disappearance of all target and all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis). Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to < 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=32 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=42 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	6.3 percentage of participants Interval 0.8 to 20.8	0.0 percentage of participants Interval 0.0 to 8.4	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 1 (Cycle 1 Day 1), 8 (Cycle 1 Day 8), and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

Population: Participants in the PK Analysis Set (participants who received any amount of magrolimab with at least one detectable post-treatment serum concentration of magrolimab) with available data were analyzed.

Cmax is defined as the maximum concentration of drug.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=10 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=7 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=15 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=14 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=11 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Pharmacokinetic (PK) Parameter: Cmax of Magrolimab Day 1 (Cycle 1 Day 1)	1.04 μg/mL Standard Deviation 0.769	0.629 μg/mL Standard Deviation 0.437	0.662 μg/mL Standard Deviation 0.374	0.432 μg/mL Standard Deviation 0.173	0.517 μg/mL Standard Deviation 0.311	0.479 μg/mL Standard Deviation 0.170	0.559 μg/mL Standard Deviation 0.254	0.525 μg/mL Standard Deviation 0.296	—
Pharmacokinetic (PK) Parameter: Cmax of Magrolimab Day 8 (Cycle 1 Day 8)	209 μg/mL Standard Deviation 82.0	230 μg/mL Standard Deviation 54.6	455 μg/mL Standard Deviation 105	558 μg/mL Standard Deviation 168	1100 μg/mL Standard Deviation 287	513 μg/mL Standard Deviation 148	616 μg/mL Standard Deviation 121	901 μg/mL Standard Deviation 131	—
Pharmacokinetic (PK) Parameter: Cmax of Magrolimab Day 29 (Cycle 2 Day 1)	312 μg/mL Standard Deviation 121	352 μg/mL Standard Deviation 68.4	728 μg/mL Standard Deviation 207	982 μg/mL Standard Deviation 182	2140 μg/mL Standard Deviation 590	—	775 μg/mL Standard Deviation 110	1790 μg/mL Standard Deviation 49.5	—

SECONDARY outcome

Timeframe: Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 8 (Cycle 1 Day 8) and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

Population: Participants in the PK Analysis Set with available data were analyzed.

Tmax is defined as the time (observed time point) of Cmax.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=9 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=7 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=9 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=14 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=11 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
PK Parameter: Tmax of Magrolimab Day 8 (Cycle 1 Day 8)	0.10 days Interval 0.09 to 0.12	0.12 days Interval 0.09 to 0.13	0.12 days Interval 0.12 to 6.94	0.14 days Interval 0.12 to 0.85	0.13 days Interval 0.12 to 3.9	0.12 days Interval 0.08 to 6.82	0.13 days Interval 0.12 to 0.17	0.12 days Interval 0.11 to 6.99	—
PK Parameter: Tmax of Magrolimab Day 29 (Cycle 2 Day 1)	0.94 days Interval 0.1 to 1.09	0.13 days Interval 0.12 to 0.13	0.13 days Interval 0.12 to 0.96	0.13 days Interval 0.1 to 0.15	0.12 days Interval 0.12 to 0.13	—	0.14 days Interval 0.14 to 0.14	0.12 days Interval 0.12 to 0.12	—

SECONDARY outcome

Timeframe: Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 8 (Cycle 1 Day 8) and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

Population: Participants in the PK Analysis Set with available data were analyzed.

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=5 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=9 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=1 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
PK Parameter: AUClast of Magrolimab Day 8 (Cycle 1 Day 8)	—	676 day*μg/mL Standard Deviation 75.3	1530 day*μg/mL Standard Deviation 513	2140 day*μg/mL Standard Deviation 726	2920 day*μg/mL Standard Deviation 600	1930 day*μg/mL	—	—	—
PK Parameter: AUClast of Magrolimab Day 29 (Cycle 2 Day 1)	1420 day*μg/mL Standard Deviation 711	1560 day*μg/mL Standard Deviation 413	3330 day*μg/mL Standard Deviation 1270	4480 day*μg/mL Standard Deviation 1220	7340 day*μg/mL Standard Deviation 2380	—	—	—	—

SECONDARY outcome

Timeframe: Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 8 (Cycle 1 Day 8) and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

Population: Participants in the PK Analysis Set with available data were analyzed.

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=4 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=7 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=4 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=1 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
PK Parameter: AUCtau of Magrolimab Day 8 (Cycle 1 Day 8)	—	676 day*μg/mL Standard Deviation 75.3	1630 day*μg/mL Standard Deviation 649	2140 day*μg/mL Standard Deviation 726	—	1930 day*μg/mL	—	—	—
PK Parameter: AUCtau of Magrolimab Day 29 (Cycle 2 Day 1)	1640 day*μg/mL Standard Deviation 604	1560 day*μg/mL Standard Deviation 413	3630 day*μg/mL Standard Deviation 1040	4480 day*μg/mL Standard Deviation 1220	8770 day*μg/mL Standard Deviation 1120	—	—	—	—

SECONDARY outcome

Timeframe: Baseline; post-treatment (assessed continuously up to 30 days after last dose; maximum 15.3 months )

Population: Immunogenicity Analysis Set included participants with at least one reported ADA result.

Percentage of Participants With Positive ADA at any timepoint was reported.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=3 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 n=10 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=7 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=6 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=16 Participants Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 n=15 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 n=15 Participants Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Percentage of Participants With Anti-drug Antibodies (ADA) Baseline ADA	0.00 percentage of participants	0.00 percentage of participants	0.00 percentage of participants	14.3 percentage of participants	0.00 percentage of participants	6.3 percentage of participants	0.00 percentage of participants	0.00 percentage of participants	—
Percentage of Participants With Anti-drug Antibodies (ADA) Post-Treatment ADA	33.3 percentage of participants	0.00 percentage of participants	0.00 percentage of participants	0.00 percentage of participants	0.00 percentage of participants	6.3 percentage of participants	13.3 percentage of participants	0.00 percentage of participants	—
Percentage of Participants With Anti-drug Antibodies (ADA) Overall ADA	33.3 percentage of participants	0.00 percentage of participants	0.00 percentage of participants	14.3 percentage of participants	0.00 percentage of participants	12.5 percentage of participants	13.3 percentage of participants	0.00 percentage of participants	—

SECONDARY outcome

Timeframe: From Screening until 38.89 months (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

Population: Participants in All Treated with available data were analyzed. Efficacy results were planned to be reported separately for all CRC participants with KRASwt and KRASm tumors.

DCR was defined as the percentage of participants with disease control which consisted of CR+PR+SD. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to < 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters measured while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=32 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=42 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Disease Control Rate (DCR) as Assessed by RECIST v1.1	50.0 percentage of participants Interval 31.9 to 68.1	38.1 percentage of participants Interval 23.6 to 54.4	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From first objective response until documented PD (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

Population: Participants in All Treated with available data were analyzed. Efficacy results were planned to be reported separately for all CRC participants with KRASwt and KRASm tumors.

DOR was measured from when the first (objective) response was met (i.e., CR or PR) until the first date of objectively documented PD. Participants who did not have objectively PD was censored at their last documented progression-free date. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to < 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Kaplan Meier estimate was used for analysis.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=2 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Duration of Response (DOR) as Assessed by RECIST v1.1	9.7 months Interval 7.0 to 12.5	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From first dose until documented PD/death (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

Population: Participants in All Treated with available data were analyzed. Efficacy results were planned to be reported separately for all CRC participants with KRASwt and KRASm tumors.

PFS was measured from first dose until the first date of objectively documented PD or death. Participants who did not have objectively documented PD and not died was censored at their last documented progression-free date. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Kaplan Meier estimate was used for analysis.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=32 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=42 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Progression Free Survival (PFS) as Assessed by RECIST v1.1	3.6 months Interval 1.8 to 5.4	1.9 months Interval 1.8 to 3.5	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From first dose until death (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

Population: Participants in All Treated with available data were analyzed. Efficacy results were planned to be reported separately for all CRC participants with KRASwt and KRASm tumors.

OS was measured from first dose until death. Participants who did not die were censored at their last known alive date. Kaplan Meier estimate was used for analysis.

Outcome measures

Measure	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2 n=32 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2 n=42 Participants Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, started on Day 1. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with solid tumor received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1.After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC who were KRASwt and were refractory to anti-EGFRmAb therapy received a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) in combination with cetuximab 250 mg/m\^2 infusions given over 60 minutes.	Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 2 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2 Participants with advanced CRC with KRASm who had progressed or were not candidates for oxaliplatin or irinotecan-based therapy received a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants also received a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab started on Day 1; Days 8 and 22 were removed from Cycle 3 onwards for magrolimab. Each cycle consisted of 4 weeks (28 days). Cetuximab was administered 1 hour prior to magrolimab infusion on days when both were given. Treatment was administered until unacceptable toxicity, voluntary withdrawal, or documented PD.	Magrolimab Priming Dose Only Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Overall Survival (OS)	9.5 months Interval 5.9 to 12.6	7.6 months Interval 5.4 to 11.7	—	—	—	—	—	—	—

Adverse Events

Magrolimab 10 mg/kg

Serious events: 3 serious events

Other events: 9 other events

Deaths: 7 deaths

Magrolimab 20 mg/kg

Serious events: 6 serious events

Other events: 10 other events

Deaths: 8 deaths

Magrolimab 30 mg/kg

Serious events: 10 serious events

Other events: 36 other events

Deaths: 30 deaths

Magrolimab 45 mg/kg

Serious events: 5 serious events

Other events: 20 other events

Deaths: 14 deaths

Magrolimab Priming Dose Only

Serious events: 1 serious events

Other events: 3 other events

Deaths: 3 deaths

Serious adverse events

Measure	Magrolimab 10 mg/kg n=9 participants at risk Participants who received magrolimab maintenance dose of 10 mg/kg in combination with cetuximab in any part of the study.	Magrolimab 20 mg/kg n=10 participants at risk Participants who received magrolimab maintenance dose of 20 mg/kg in combination with cetuximab in any part of the study.	Magrolimab 30 mg/kg n=36 participants at risk Participants who received magrolimab maintenance dose of 30 mg/kg in combination with cetuximab in any part of the study.	Magrolimab 45 mg/kg n=20 participants at risk Participants who received magrolimab maintenance dose of 45 mg/kg in combination with cetuximab in any part of the study.	Magrolimab Priming Dose Only n=3 participants at risk Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Blood and lymphatic system disorders Anaemia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Blood and lymphatic system disorders Immune thrombocytopenic purpura	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Cardiac disorders Bradycardia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Constipation	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Enterocolitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Faecaloma	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Small intestinal obstruction	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Complication associated with device	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Pyrexia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Bacterial sepsis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Cystitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Post procedural infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Urinary tract infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Bilirubin conjugated increased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations International normalised ratio increased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Dehydration	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Pathological fracture	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Cerebrovascular accident	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Acute kidney injury	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Haemorrhage	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.

Other adverse events

Measure	Magrolimab 10 mg/kg n=9 participants at risk Participants who received magrolimab maintenance dose of 10 mg/kg in combination with cetuximab in any part of the study.	Magrolimab 20 mg/kg n=10 participants at risk Participants who received magrolimab maintenance dose of 20 mg/kg in combination with cetuximab in any part of the study.	Magrolimab 30 mg/kg n=36 participants at risk Participants who received magrolimab maintenance dose of 30 mg/kg in combination with cetuximab in any part of the study.	Magrolimab 45 mg/kg n=20 participants at risk Participants who received magrolimab maintenance dose of 45 mg/kg in combination with cetuximab in any part of the study.	Magrolimab Priming Dose Only n=3 participants at risk Participants who received only the priming dose (1 mg/kg) of magrolimab in Phase 2 of the study.
Infections and infestations Herpes zoster	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Lung infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Nail infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Paronychia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Pharyngitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Sinusitis	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Blood and lymphatic system disorders Anaemia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.6% 11/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 4/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Blood and lymphatic system disorders Immune thrombocytopenic purpura	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Blood and lymphatic system disorders Lymph node pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Blood and lymphatic system disorders Lymphopenia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Cardiac disorders Palpitations	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Cardiac disorders Tachycardia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Ear and labyrinth disorders Deafness	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Ear and labyrinth disorders Tinnitus	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Blepharal pigmentation	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Conjunctivitis allergic	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Dry eye	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Photopsia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Strabismus	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Vision blurred	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Eye disorders Vitreous floaters	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Abdominal distension	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	11.1% 4/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Abdominal pain	33.3% 3/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	16.7% 6/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	66.7% 2/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Ascites	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Constipation	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	50.0% 5/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	16.7% 6/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 6/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Diarrhoea	44.4% 4/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 9/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	35.0% 7/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Dry mouth	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Dyspepsia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Dysphagia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Enterocolitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Gastrooesophageal reflux disease	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Glossodynia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Hypoaesthesia oral	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Loose tooth	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Nausea	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	44.4% 16/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	15.0% 3/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Oesophageal pain	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Rectal discharge	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Stomatitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	22.2% 8/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 6/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Gastrointestinal disorders Vomiting	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.6% 11/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 4/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Chest discomfort	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Chest pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Chills	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.6% 11/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 5/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Early satiety	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Fatigue	44.4% 4/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	50.0% 5/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	50.0% 18/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	35.0% 7/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Gait disturbance	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Influenza like illness	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Non-cardiac chest pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Oedema	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Oedema peripheral	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Performance status decreased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
General disorders Pyrexia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	36.1% 13/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	40.0% 8/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Bronchitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Conjunctivitis	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Cystitis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Folliculitis	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Gastroenteritis viral	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Skin infection	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Tinea cruris	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Tooth abscess	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Upper respiratory tract infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Vaginal infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Injury, poisoning and procedural complications Fall	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Injury, poisoning and procedural complications Gastrointestinal stoma complication	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Injury, poisoning and procedural complications Infusion related reaction	33.3% 3/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 12/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	35.0% 7/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Alanine aminotransferase increased	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	11.1% 4/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Aspartate aminotransferase increased	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	13.9% 5/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Blood alkaline phosphatase increased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Blood bilirubin increased	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	13.9% 5/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 5/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Blood lactate dehydrogenase increased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Blood sodium decreased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Electrocardiogram QT prolonged	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Lymphocyte count decreased	44.4% 4/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	15.0% 3/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Platelet count decreased	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations Weight decreased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Investigations White blood cell count decreased	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Decreased appetite	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 9/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 5/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Dehydration	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	11.1% 4/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	15.0% 3/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hyperglycaemia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hypokalaemia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	13.9% 5/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 4/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hypomagnesaemia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	40.0% 4/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	27.8% 10/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 5/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Hypophosphataemia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Iron deficiency	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Lactic acidosis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Metabolism and nutrition disorders Malnutrition	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Arthralgia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Back pain	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	13.9% 5/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	11.1% 4/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Myalgia	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Musculoskeletal and connective tissue disorders Neck pain	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Cerebral infarction	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Dizziness	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Dysaesthesia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Dysgeusia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Headache	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 2/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	47.2% 17/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	40.0% 8/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Presyncope	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Restless legs syndrome	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Somnolence	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Syncope	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Nervous system disorders Tremor	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Psychiatric disorders Anxiety	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Psychiatric disorders Confusional state	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Psychiatric disorders Depression	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 4/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Psychiatric disorders Insomnia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	15.0% 3/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Psychiatric disorders Mental disorder	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Psychiatric disorders Restlessness	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Dysuria	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Haematuria	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Hydronephrosis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Pollakiuria	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Urinary hesitation	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Renal and urinary disorders Urinary retention	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	13.9% 5/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	20.0% 4/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Dysphonia	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Dyspnoea	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.6% 11/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	15.0% 3/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Laryngeal haemorrhage	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Nasal congestion	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Pulmonary congestion	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Acne	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Dermatitis acneiform	44.4% 4/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	50.0% 5/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	38.9% 14/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 6/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Dry skin	66.7% 6/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	22.2% 8/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	50.0% 10/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Ingrowing nail	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Pruritus	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	19.4% 7/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Rash	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 1/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	19.4% 7/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Rash maculo-papular	22.2% 2/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	30.0% 3/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	19.4% 7/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	25.0% 5/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	8.3% 3/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	11.1% 4/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Deep vein thrombosis	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Flushing	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	2.8% 1/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Hypertension	11.1% 1/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	10.0% 2/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Hypotension	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.6% 2/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	33.3% 1/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Jugular vein thrombosis	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.
Vascular disorders Raynaud's phenomenon	0.00% 0/9 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/10 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/36 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	5.0% 1/20 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.	0.00% 0/3 • Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months All Treated participants included all participants who received at least 1 dose of any study drugs. Per planned analysis, AE data were summarized by the magrolimab maintenance dose level.

Additional Information

Gilead Clinical Study Information Center

Gilead Sciences

Phone: 1-833-445-3230 (GILEAD-0)

Email: GileadClinicalTrials@gilead.com

Results disclosure agreements

• Principal investigator is a sponsor employee After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
• Publication restrictions are in place

Restriction type: OTHER